An observational study in Sarcopenia and Acute Stroke, sponsored by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba). Recruiting at 1 site in Russia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) · Observational
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:
Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?
Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
This study's planned enrollment of 400 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Browse Sarcopenia studies →University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises patients with acute ischemic stroke admitted within the first 72 hours after symptom onset.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Discontinuation criteria (drop-out)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change from Baseline in Barthel Index for Activities of Daily Living at 14 days
Lower scores indicate increasing disability and a greater need for skilled care. Min - 0 ( \< 20 - totally dependent), max - 100 ( \> 80 - independent).
Time frame: Baseline and 14 days
Change from Baseline in Modified Rankin scale at 90 days
Min - 0 (no disability), max - 6 (dead). A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.
Time frame: Baseline and 90 days
Number of Participants with sarcopenia
Time frame: Baseline
Change from Baseline in arm muscle mass at 14 and 28 days.
Mid-upper arm circumference: measured at the midpoint between the acromion and the olecranon with the arm relaxed (2 measurements) in cm. Arm muscle circumference and area are calculated using the Heymsfield formula.
Time frame: Baseline, 14 and 28 days
Change from Baseline in calf circumference at 14 and 28 days
Calf circumference: measured in the seated position, with the knee at a right angle, at the widest part of the non-paretic calf, with the tape snug but without compression (2 measurements) in cm. Calf circumference below 34 cm in men and 33 cm in women is classified as reduced.
Time frame: Baseline, 14 and 28 days
Change from Baseline in handgrip strength at 14 and 28 days.
Handgrip dynamometry: performed in the seated position with the elbow at a right angle; three trials on the non-paretic hand, with the mean value used for analysis. Handgrip strength of the non-paretic hand below 27 kg in men and 16 kg in women is classified as reduced.
Time frame: Baseline, 14 and 28 days.
Correlations between anthropometric measures and ultrasound/CT parameters
Time frame: Baseline, 14, 28, and 90 days
Change from Baseline in National Institutes of Health Stroke Scale (NIHSS) at 24 hours, 7 and 14 days.
Min - 0, max - 42. A higher score means a patients has more severe symptoms. Patients with a score of \<4 are highly likely to have good clinical outcomes.
Time frame: Baseline, 24 hours, 7 and 14 days.
Change from Baseline in Rivermead Mobility Index at 14 and 28 days.
Min - 0, max - 15. Higher scores indicate better mobility performance. A score of 0 indicates an inability to complete any of the 15 tasks.
Time frame: Baseline, 14 and 28 days.
Mortality at 14 and 90 days
Mortality rate at 14 and 90 days
Time frame: 14 and 90 days
Hospital length of stay
Days. Total number of days spent admitted to the hospital during the index hospital stay, calculated from admission date to final discharge date.
Time frame: Up to 28 days
Intensive care unit length of stay
Days. Total number of days spent in the intensive care unit from the time of initial ICU admission to successful transfer or discharge to a step-down unit.
Time frame: Up to 28 days
Number of Participants with recurrent events within 90 days
Time frame: From baseline to 90 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 40 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 40 months is above that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)